Many recent NACDS RxIMPACT pharmacy tours have been directly with members of Congress themselves—68 percent so far this year.
Members of Congress were able to grasp firsthand critical pharmacy public policy issues when they toured pharmacies in their home states and congressional districts.
During the Fourth of July congressional recess, members of Congress learned firsthand about key pharmacy issues—particularly about the need for direct and indirect remuneration (DIR) fee relief as part of a drug-pricing legislative package.
DIR Fee Relief is Focus of Largest-Ever NACDS RxIMPACT Push Effort underway to help advance Phair Pricing Act
DIR fee relief is motivating a record-breaking NACDS RxIMPACT Congressional letter-writing campaign. The effort to end the abuse of DIR fees includes three focuses right now. Learn more.
Pharmacy “DIR Fee” Loophole Must Close, NACDS RxIMPACT Urges Grassroots engagement supporting Phair Pricing Act is crucial for pharmacy viability and to reduce seniors' out-of-pocket drug costs
Grassroots engagement supporting Phair Pricing Act is crucial for pharmacy viability and to reduce seniors' out-of-pocket drug costs.
Rep. Ami Bera (D-CA) recognized the importance of pharmacists as accessible healthcare providers during a Costco pharmacy tour as part of the NACDS RxIMPACT program.
"On social media, we saw a photo of NACDS Board of Directors member Richard Ashworth, president, operations, Walgreen Co., at a white board in the office of U.S. Sen. Bill Cassidy (R-LA), literally drawing out an example for the Senator that demonstrates the need for fair pharmacy reimbursement, for transparency in the prescription drug supply chain, and for appropriate pharmacy metrics that should be tethered to DIR fee reform."